The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
One concern about repeated intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in wet age related macular degeneration, is that in addition to blocking the proteins that triggers the development and proliferation of abnormal vessels in the center of the retina, they may also result in changes in the normal vessels that feeds the outer part of the retina.
Small vessels with fenestrations (such as those that feed the outer part of the retina, which are called choriocapillaris) appear to be especially sensitive to this protein (called vascular endothelial growth factor, VEGF) withdrawal.
It is estimated that global blood flow in the vascular layer under the retina (called choroid) may be indirectly assessed by measuring the amplitude of the ocular pulsation (the pressure inside the eye change according to the cardiac cycle, similar to the change in blood pressure) which is called Ocular Pulse Amplitude (OPA). The Pascal Dynamic Contour Tonometer (Pascal DCT) is a new tonometer (a device which measures the pressure within the eye) designed to measure intraocular pressure and ocular pulse amplitude.
No published study has yet assessed the effect of bevacizumab (Avastin) or ranibizumab (Lucentis) treatment for wet AMD (or on any other retinal disease) on OPA. This is our aim in this pilot study, in which we will measure the pressure within the eye just prior to bevacizumab/Ranibizumab treatment, followed by repeated measurements a week and a month after the treatment.
For this purpose, up to 60 patients with wet AMD will be recruited.
| Condition | Intervention |
|---|---|
|
Neovascular Age Related Macular Degeneration |
Device: Pascal Dynamic Contour Tonometer Drug: Ranibizumab Drug: Bevacizumab |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | The Effect of Intravitreal Bevacizumab & Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration |
- Ocular pulse pressure (OPA)a week and month after intravitreal bevacizumab/ranibizumab, as compare to baseline OPA, just prior to treatment [ Time Frame: One month for each patient ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 60 |
| Study Start Date: | August 2007 |
| Estimated Study Completion Date: | February 2009 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
All study patients will be evaluated in a similar way
|
Device: Pascal Dynamic Contour Tonometer
Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
Other Name: Pascal Dynamic Contour Tonometer = Pascal DCT
Drug: Ranibizumab
measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
Other Name: Lucentis
Drug: Bevacizumab
measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
Other Name: Avastin
|
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female in the ages of 50 year or older
- Willing and able to sign an inform consent
Exclusion Criteria:
- Any history, signs or symptoms of any retinal or optic nerve disease, except AMD and mild hypertensive retinopathy
- In the presently bevacizumab/ranibizumab treated eye, prior PDT and/or intravitreal Kenalog, during the last 3 months.
- History of ocular surgery with the following exception: extra capsular cataract extraction with implantation of a posterior chamber intra-ocular lens.
- History of ocular laser treatment, with the following exceptions: Posterior capsulotomy following cataract surgery.
- Cataract or other media opacity precluding adequate fundus visualization of both eyes
Contacts and Locations| Contact: Ehud Rechtman, MD | 972-52-2528871 | ehudrechtman@gmail.com |
| Belgium | |
| University Hospitals Leuven | Recruiting |
| Leuven, Belgium | |
| Contact: Ingeborg Stalmans, MD, PhD | |
| Israel | |
| Goldschleger Eye Institute Sheba Medical Center | Recruiting |
| Ramat Gan, Israel, 52621 | |
| Contact: Ehud Rechtman, MD 972-52-2528871 ehudrechtman@gmail.com | |
| Principal Investigator: Ehud Rechtman, MD | |
| Principal Investigator: | Ehud Rechtman, MD | Sheba Medical Center |
More Information
No publications provided
| Responsible Party: | Ehud Rechtman MD, Goldschleger Eye Institute, Sheba Medical Center |
| ClinicalTrials.gov Identifier: | NCT00640640 History of Changes |
| Other Study ID Numbers: | SHEBA-07-4739-ER-CTIL |
| Study First Received: | February 24, 2008 |
| Last Updated: | March 20, 2008 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Sheba Medical Center:
|
IOP OPA AMD bevacizumab ranibizumab |
choroidal blood flow DCT Ocular Pulse Amplitude change following anti VEGF Ocular Pulse Amplitude |
Additional relevant MeSH terms:
|
Macular Degeneration Wet Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases Bevacizumab Angiogenesis Inhibitors |
Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Pharmacologic Actions Growth Inhibitors Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013